TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15528 · Feb 28

#python#agent#android#app#automation#copilot#gui#mllm#mobile#mobile_agents#multimodal#multimodal_agent#multimodal_large_language_models Mobile-Agent-v3.5 is Alibaba's top GUI agent family using GUI-Owl 1.5 models (2B to 235B sizes) for automating desktop, mobile, and browser tasks like stock checks, bookings, or document creation with planning, reflection, and memory. Try free online demos on ModelScope or Bailian, or use limited-time APIs—no setup needed. It leads 20+ benchmarks for real-world use. You benefit by saving time on repetitive tasks, boosting productivity, and handling complex operations hands-free across devices. https://github.com/X-PLUG/MobileAgent

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment